Kidney cancer patients in Real-World clinics get immunotherapy: does it work?
NCT ID NCT03455452
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in everyday medical practice. The main goal was to see how long patients lived overall, with secondary goals including how long the cancer stayed under control and how well the drugs shrank tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab with or without ipilimumab
- What this could lead to
- If successful, this study could confirm that these immunotherapy drugs work as well in everyday practice as they did in clinical trials, helping doctors make better treatment decisions.
- What could go wrong
- This is an observational study, not a controlled experiment, so results may be influenced by patient differences. It cannot prove cause and effect, only describe what happened in real life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF KIDNEY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Paris, 75002, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?